Literature DB >> 24094488

Genomic alterations in human umbilical cord-derived mesenchymal stromal cells call for stringent quality control before any possible therapeutic approach.

Alessandro Borghesi1, Maria Antonietta Avanzini, Francesca Novara, Melissa Mantelli, Elisa Lenta, Valentina Achille, Rosa Maria Cerbo, Chryssoula Tzialla, Stefania Longo, Annalisa De Silvestri, Luc J I Zimmermann, Paolo Manzoni, Marco Zecca, Arsenio Spinillo, Rita Maccario, Orsetta Zuffardi, Mauro Stronati.   

Abstract

BACKGROUND AIMS: The umbilical cord (UC) is a promising source of mesenchymal stromal cells (MSCs). UC-MSCs display very similar in vitro characteristics to bone marrow-MSCs and could represent a valuable alternative for cell-based therapies. However, it is still unclear whether UC-MSCs are prone or not to the acquisition of genomic imbalances during in vitro expansion.
METHODS: With the use of array-comparative genomic hybridization, we compared copy number variations of early (P2-P3) and late (>P5) passages of in vitro-expanded UC-MSCs.
RESULTS: In two of 11 long-term UC-MSCs cultures, we observed the appearance of clones carrying genomic imbalances, which generated genetic mosaicism at intermediate passages. Although still able to reach the senescence phase, the cells carrying the genomic imbalance acquired a proliferative advantage, as demonstrated by the increase in frequency during long-term culture.
CONCLUSIONS: Altogether, our results suggest that UC-MSC-based clinical protocols should be designed with caution; their clinical use should be preceded by array-comparative genomic hybridization screening for the acquisition of genomic imbalances during in vitro expansion.
Copyright © 2013 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  array comparative genomic hybridization; karyotype; mesenchymal stromal cells; umbilical cord

Mesh:

Year:  2013        PMID: 24094488     DOI: 10.1016/j.jcyt.2013.06.006

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  9 in total

1.  Engineered Mesenchymal Stem Cells as an Anti-Cancer Trojan Horse.

Authors:  Adam Nowakowski; Katarzyna Drela; Justyna Rozycka; Miroslaw Janowski; Barbara Lukomska
Journal:  Stem Cells Dev       Date:  2016-09-07       Impact factor: 3.272

2.  Differential expression of cell cycle and WNT pathway-related genes accounts for differences in the growth and differentiation potential of Wharton's jelly and bone marrow-derived mesenchymal stem cells.

Authors:  Aristea K Batsali; Charalampos Pontikoglou; Dimitrios Koutroulakis; Konstantia I Pavlaki; Athina Damianaki; Irene Mavroudi; Kalliopi Alpantaki; Elisavet Kouvidi; George Kontakis; Helen A Papadaki
Journal:  Stem Cell Res Ther       Date:  2017-04-26       Impact factor: 6.832

Review 3.  Stem cell therapy for preventing neonatal diseases in the 21st century: Current understanding and challenges.

Authors:  Christopher R Nitkin; Johnson Rajasingh; Courtney Pisano; Gail E Besner; Bernard Thébaud; Venkatesh Sampath
Journal:  Pediatr Res       Date:  2019-05-14       Impact factor: 3.756

4.  Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection.

Authors:  Maria A Avanzini; Manuela Mura; Elena Percivalle; Francesca Bastaroli; Stefania Croce; Chiara Valsecchi; Elisa Lenta; Giulia Nykjaer; Irene Cassaniti; Jessica Bagnarino; Fausto Baldanti; Marco Zecca; Patrizia Comoli; Massimiliano Gnecchi
Journal:  Stem Cells Transl Med       Date:  2021-01-26       Impact factor: 6.940

Review 5.  Headway and the remaining hurdles of mesenchymal stem cells therapy for bronchopulmonary dysplasia.

Authors:  Eireen Tang; Mariam Zaidi; Wen-Huey Lim; Vijayendran Govindasamy; Kong-Yong Then; Khong-Lek Then; Anjan Kumar Das; Soon-Keng Cheong
Journal:  Clin Respir J       Date:  2022-09-02       Impact factor: 1.761

6.  Genetic evaluation of mesenchymal stem cells.

Authors:  Déborah Afonso Cornélio; Silvia Regina Batistuzzo de Medeiros
Journal:  Rev Bras Hematol Hemoter       Date:  2014-06-02

Review 7.  "Good things come in small packages": application of exosome-based therapeutics in neonatal lung injury.

Authors:  Gareth R Willis; S Alex Mitsialis; Stella Kourembanas
Journal:  Pediatr Res       Date:  2017-11-22       Impact factor: 3.756

8.  Cytogenetic and Transcriptomic Analysis of Human Endometrial MSC Retaining Proliferative Activity after Sublethal Heat Shock.

Authors:  Mariia A Shilina; Tatiana M Grinchuk; Olga V Anatskaya; Alexander E Vinogradov; Larisa L Alekseenko; Artem U Elmuratov; Nikolai N Nikolsky
Journal:  Cells       Date:  2018-10-25       Impact factor: 6.600

Review 9.  Principal Criteria for Evaluating the Quality, Safety and Efficacy of hMSC-Based Products in Clinical Practice: Current Approaches and Challenges.

Authors:  Juan Antonio Guadix; Javier López-Beas; Beatriz Clares; José Luis Soriano-Ruiz; José Luis Zugaza; Patricia Gálvez-Martín
Journal:  Pharmaceutics       Date:  2019-10-24       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.